Study Stopped
Study was associated with a declining population - COVID 19. Difficulty recruiting participants.
Low-Level Laser Therapy Treatment of Lung Inflammation in Post-COVID-19 Recovery
1 other identifier
observational
5
1 country
7
Brief Summary
An informational evaluation of COVID-19 patients who receive low-level laser therapy in addition to a normal regimen of treatment for symptoms associate with COVID-19. Results are compared to statistical observations published in literature from patients receiving standard care for COVID-19 symptoms without low-level laser therapy.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for all trials
Started Feb 2022
Shorter than P25 for all trials
7 active sites
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
February 24, 2022
CompletedStudy Start
First participant enrolled
February 24, 2022
CompletedFirst Posted
Study publicly available on registry
February 28, 2022
CompletedPrimary Completion
Last participant's last visit for primary outcome
November 21, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
November 21, 2022
CompletedNovember 28, 2022
February 1, 2022
9 months
February 24, 2022
November 21, 2022
Conditions
Outcome Measures
Primary Outcomes (1)
Decreased inflammation of the lungs
Inflammation of the lungs is decreased more for patients treated with LLLT in addition to the standard treatments for COVID-19 than patients who do not receive LLLT treatments as compared to literature studies available for comparison. The decrease in inflammation is measured by showing statistical improvements in O2 saturation, D-Dimer levels, C-reactive Protein, and IL-6 levels.
3 weeks
Secondary Outcomes (1)
Subjective assessment of overall health
3 weeks
Interventions
Treatment with red LED light using UltraSlim device.
Eligibility Criteria
Adults who have been infected with COVID-19, but no longer active virus, and who have lingering acute respiratory effects from infection.
You may qualify if:
- Participant is diagnosed with COVID-19
- Study participant is 18 years of age or older
- Patient exhibiting moderate-to-acute respiratory distress
You may not qualify if:
- Photosensitive condition or medication
- Active chemotherapy treatment or other cancer treatment
- Autoimmune Disorder
- Pregnant, possibly pregnant or planning pregnancy prior to the end of study participation
- Under 18
- Active cancer
- pre-existing pulmonary disease (asthma chronic bronchitis, emphasema
- Developmental disability or cognitive impairment that, in the opinion of the investigator, would preclude adequate comprehension of the informed consent form and/or ability to record the necessary study measurements
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (7)
MD at Bedside
Berkeley, California, 94705, United States
Health Atlast
Los Angeles, California, 90066, United States
Longevity
Santa Monica, California, 90025, United States
Wellness Junction
Millsboro, Delaware, 19966, United States
Diet MD
Honolulu, Hawaii, 96817, United States
Diet MD
‘Ewa Beach, Hawaii, 96706, United States
Healing Health Services
Brooklyn, New York, 11238, United States
MeSH Terms
Conditions
Interventions
Condition Hierarchy (Ancestors)
Intervention Hierarchy (Ancestors)
Study Design
- Study Type
- observational
- Observational Model
- CASE ONLY
- Time Perspective
- PROSPECTIVE
- Sponsor Type
- INDUSTRY
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
February 24, 2022
First Posted
February 28, 2022
Study Start
February 24, 2022
Primary Completion
November 21, 2022
Study Completion
November 21, 2022
Last Updated
November 28, 2022
Record last verified: 2022-02